TLX — Telix Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- AU$5.63bn
- AU$5.96bn
- $516.38m
Annual cashflow statement for Telix Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | fx Final | fx Final |
| Changes in Working Capital | 7.89 | 9.1 | 13.1 | -9.73 | -16.5 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 1.35 | -44.5 | -44.3 | 15.9 | 28.4 |
| Capital Expenditures | -0.222 | -1 | -9.61 | -7.16 | -32 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.529 | -1.04 | -2.17 | -9.75 | -57.2 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.751 | -2.05 | -11.8 | -16.9 | -89.1 |
| Financing Cash Flow Items | -0.089 | 0 | -5.42 | 0 | -9.81 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 23.5 | 2.14 | 121 | 6.76 | 421 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 22.9 | -42 | 65.4 | 4.58 | 387 |